Table 2 Subgroup characteristics
Total subgroup analyses planned or conducted (n = 66) | |
|---|---|
Pre-specified subgroup analyses | 56 |
Pre-specified subgroup analyses conducted (% of planned) | 17 (30.4%) |
 Subgroup effects reported (% of pre-specified conducted) | 6 (35.3%) |
  Stroke risk (n)a | 1 (1.8%) |
  Age (n)b | 1 (1.8%) |
  Sex (n)c | 1 (1.8%) |
  Country/race (n)d | 1 (1.8%) |
  Indication (n)e | 1 (1.8%) |
  Anticoagulation self-management (n)f | 1 (1.8%) |
Post hoc subgroup analyses conducted | 10 |
 Subgroup effects reported (% of post hoc conducted) | 8 (80%) |
  Anticoagulation: dose, route, type, or quality (n)g | 5 (50.0%) |
  Type of antiarrhythmic (n)h | 1 (10.0%) |
  Older and newer quinidine studies (n)i | 1 (10.0%) |
  Concomitant antiplatelet use (n)j | 1 (10.0%) |
Total pre-specified or post hoc subgroup analyses conducted | 27 |
 Subgroup effects reported (% of all conducted) | 14 (51.9%) |